WOBURN, Mass.--(BUSINESS WIRE)--Jan. 7, 2020--
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage
biotechnology company focused on harnessing the body’s innate biology to
repair or reverse damage caused by a broad range of degenerative
diseases, today announced that Chief Executive Officer David L. Lucchino
will present a Company overview at the 38th annual J.P.
Morgan Healthcare conference.
Mr. Lucchino’s presentation will take place on Wednesday, January 15th
at 11 a.m. PT (2 p.m. ET) in the Elizabethan A room at the Westin St.
Francis Hotel in San Francisco. The presentation will be followed by a
question and answer session to be held in the Sussex room at 11:30 a.m.
PT (2:30 p.m. ET). A live webcast of the both the presentation and the
breakout session can be accessed on the investors section of the
Frequency’s website, investors.frequencytx.com,
or by linking here.
A replay of the presentation will be posted on the Frequency website
following the event.
About Frequency Therapeutics
Frequency Therapeutics is a leader in the development of medicines
designed to activate progenitor cells within the body to treat
degenerative diseases. The Company’s progenitor cell activation (PCA)
approach stimulates progenitor cells to create functional tissue with
the aim of developing disease modifying therapies. The Company’s lead
product candidate, FX-322, is designed to regenerate auditory hair cells
to restore hearing function. In a FX-322 Phase 1/2 study, statistically
significant and clinically meaningful improvements in key measures of
hearing function in patients with sensorineural hearing loss were
observed. The Company also is evaluating additional diseases where its
PCA approach could create functional tissue, including a development
program in multiple sclerosis.
Headquartered in Woburn, Mass., Frequency has a license and
collaboration agreement with Astellas Pharma Inc. for FX-322, for which
it retains U.S. rights, as well as additional collaboration and
licensing agreements with academic and nonprofit research organizations
including The Scripps Research Institute, Massachusetts Eye and Ear,
Partners Healthcare and the Massachusetts Institute of Technology. For
more information, visit www.frequencytx.com
and follow Frequency on Twitter @Frequencytx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005231/en/
Source: Frequency Therapeutics
Carlo Tanzi, Ph.D.
Scient Public Relations